FLUZONE HIGH-DOSE VACCINE is proven in a head-to-head randomized controlled trial to prevent more cases of influenza in adults 65+ compared with Fluzone vaccine.1,2 Since 2010, more than 110 million doses of Fluzone High-Dose have been sold in the United States.3


Proven Efficacy

Results from the clinical trial were published in the New England Journal of Medicine

Primary Endpoint
24.2%
Better Protection
from Influenza
compared with Fluzone vaccine1,2
Primary endpoint of the study was the occurrence of laboratory‑confirmed, protocol-defined, influenza-like illness caused by viral strains regardless of their antigenic similarity to vaccine components.
Secondary Endpoint
51.1%
Better Protection
from Influenza
compared with Fluzone vaccine1,2
A secondary endpoint of the study was the occurrence of culture-confirmed influenza caused by viral types/subtypes antigenically similar to those contained in the respective annual vaccine formulations in association with a modified Centers for Disease Control and Prevention-defined influenza-like illness.

In a randomized controlled trial for immunogenicity and safety, the most common local and systemic adverse reactions to Fluzone High‑Dose vaccine include pain at the injection site, myalgia, malaise and headache.4

Safety Information:

  • In adults 65+ (N=3,833)1
  • Across multiple strains of influenza: A (H1N1), A (H3N2), and B2

Fluzone High-Dose Vaccine Injection-Site and System Reactions Fluzone High-Dose Vaccine Injection-Site and System Reactions

Fluzone High-Dose Unique Features

  • The only senior influenza vaccine with superior efficacy compared with Fluzone vaccine1,2,b
  • Last year, nearly two-thirds of adults 65+ who were vaccinated against the flu received Fluzone High-Dose vaccine5
  • 4x the amount of antigen per strain of Fluzone vaccine1,2

b Per-protocol analysis set for efficacy assessments.1